Balyasny Asset Management
VERA icon

Balyasny Asset Management’s Vera Therapeutics VERA Stock Holding History

Balyasny Asset Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.1M Sell
374,951
-44,619
-11% -$1.66M 0.02% 827
2026
Q1 		$16.9M Buy
419,570
+365,243
+672% +$15.7M 0.02% 759
2025
Q4 		$2.75M Buy
+54,327
New +$1.93M ﹤0.01% 1715
2025
Q1 		– Sell
-385,425
Closed -$16.3M – 3318
2024
Q4 		$16.3M Buy
385,425
+209,834
+120% +$9.29M 0.02% 756
2024
Q3 		$7.76M Buy
175,591
+169,544
+2,804% +$6.43M 0.01% 1066
2024
Q2 		$219K Buy
+6,047
New +$240K ﹤0.01% 2314
2024
Q1 		– Sell
-10,430
Closed -$160K – 3154
2023
Q4 		$160K Buy
+10,430
New +$132K ﹤0.01% 2343

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Balyasny Asset Management's VERA Position: Q2 2026 in Review

Balyasny Asset Management reduced its Vera Therapeutics (VERA) stake by 11% in Q2 2026, selling an estimated $1.66M and leaving 374,951 shares worth $16.1M. The position accounts for 0.02% of the portfolio, ranked #827.

Balyasny Asset Management first reported a position in VERA in Q4 2023 and has held it in 7 quarters since. The position peaked at $16.9M in Q1 2026. 219 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Balyasny Asset Management held 374,951 shares of Vera Therapeutics worth $16.1M as of Q2 2026.
  • Balyasny Asset Management sold 44,619 Vera Therapeutics shares in Q2 2026, an estimated $1.66M.
  • Vera Therapeutics made up 0.02% of Balyasny Asset Management's portfolio in Q2 2026, its #827 holding.
  • Balyasny Asset Management first reported a position in Vera Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • Balyasny Asset Management's Vera Therapeutics position peaked at $16.9M in Q1 2026.
  • 219 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.